An observational study in Female Infertility and Gene Deregulation, sponsored by Infertility Treatment Center Dortmund. Completed at 1 site in Germany. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Infertility Treatment Center Dortmund · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Infertility, Female with a site in Germany — none open to participants now, 2 under way, none of them phase 3. Infertility, Female · Germany.
Among the 12 studies in Infertility, Female with a site in Germany, this one is one of 2 that started in 2018, is one of 7 observational ones, and was the 7th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →None of the 12 studies in Infertility, Female with a site in Germany is open now. The open studies under Infertility, Female, anywhere →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is close to the median of 160 across 163 observational studies indexed under Infertility, Female.
Median enrollment 114 across the 5 interventional studies, 156 across the 7 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 7 most frequent:
Infertility Treatment Center Dortmund is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Infertility Treatment Center Dortmund has 4 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
1 of the studies in Infertility, Female with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179993Infertility Treatment Center DortmundDetection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Infertility, Female with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is increasing evidence that exposure to environmental factors in early development is associated with an increased risk of metabolic and other common diseases. These increased disease risks are likely due to environmental-induced epigenetic changes leading to dysregulation of genes and signaling cascades. The best studied epigenetic modification in this context is DNA methylation. Preliminary studies have already shown that an increased father age or intracytoplasmic sperm injection affects methylation pattern in sperm or umbilical cord blood of children. Unlike sperm, less is known about the methylation of human oocytes and their susceptibility to environmental factors. The aim of this study is to analyze the methylation pattern of immature oocytes of women with decreased fertility. Based on the results of a large number of oocytes from different women, risk assessments could be made for individual factors such as the age of the patient, as well as correlations between the occurrence of changes in gene expression and the unfulfilled desire to have children. In addition, the methylation patterns in sperm from 20 patients are to be examined as reference patterns.
Although more than five million children have been conceived worldwide through Assisted Reproduction Techniques (ARTs), little is known about potential effects of ART in later life. So far, the focus of reproductive research is based on the success rate of infertility treatment. There is increasing evidence that exposure to environmental substances, age of the patient or in vitro culture conditions in early development is associated with a life-long increased risk of metabolic and other common diseases. These increased disease risks are likely due to environmental-induced epigenetic changes leading to dysregulation of genes and signaling cascades. These include Beckwith-Wiedemann and Angelman syndrome.
The best studied epigenetic modification in this context is DNA methylation, which regulates the gene expression in a temporally and highly coordinated manner. Preliminary studies have already shown that an increased father age influences the pattern of methylation in the sperm and umbilical cord blood of children. Moreover, intracytoplasmic sperm injection (ICSI) also leaves epigenetic signatures in umbilical cord blood. Unlike sperm, little is known about the methylation of human oocytes and their susceptibility to environmental factors. The main reason for this is the difficulty of collecting human oocytes in sufficient numbers for genome-wide analysis. The aim of this study is to analyze the methylation pattern of immature oocytes, which are not suitable for further ICSI treatment, of women with decreased fertility. The products of gene expression and also the methylation of the DNA itself can be investigated using newly developed DNA sequencing methods. Based on the results of a large number of oocytes from different women, risk assessments could be made for individual factors such as the age of the patient, as well as correlations between the occurrence of changes in gene expression and the unfulfilled desire to have children. In addition, the methylation patterns in sperms from 20 patients are to be examined as reference.
female patients seeking ICSI treatment because of male subfertility
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ICSI treatment because of male subfertility
Methylation pattern
Analysis of methylation pattern in immature oocytes (not suitable for further ICSI treatment). Methylation will be pointed out as number of methylated gene loci in comparison to the overall amount of analyzed gene loci.
Time frame: 1 day (Directly after oocyte pick-up)
Gene expression
Analysis of gene expression in immature oocytes (not suitable for further ICSI treatment) will be done by quantification of selected gene transcripts (in picogram).
Time frame: 1 day (Directly after oocyte pick-up)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Jul 2024, 72 months.
Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's 72 months is above that.
Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Infertility Treatment Center Dortmund